Calimmune Acquired For $91M

Pasadena-based Calimmune, a biotechnology company focused on stem cell therapy, has been acquired by CSL Behring, CSL said on Monday, in a deal worth $91M up front, but worth up to $400M total when you include possible earn out. Calimmune has R&D facilities in both Pasadena, California and Sydney, Australia. Calimmune's lead product is CAL-H, an HSC gene therapy for the treatment of sickle cell disease. CSL said that the deal has potential, performance based milestones of up to $325M over a period of eight years.